MK-2866 — also designated GTX-024 and commonly known as Ostarine or Enobosarm — is a non-steroidal selective androgen receptor modulator (SARM) developed by GTx, Inc. Unlike classical androgens such as testosterone, MK-2866 was engineered to activate androgen receptors in specific tissues while minimising activity in others. Understanding its mechanism of action requires examining receptor binding, conformational changes, downstream transcriptional events, and the pharmacokinetic parameters that determine its behaviour in biological systems.

This overview is intended for researchers working with reference-grade MK-2866 in in-vitro settings. It is not medical advice. MK-2866 is not approved by the Therapeutic Goods Administration (TGA) or any equivalent regulatory body for human use.

Androgen Receptor Structure and the SARM Binding Model

The androgen receptor (AR) is a member of the nuclear receptor superfamily — a ligand-activated transcription factor that, upon binding an agonist, translocates to the nucleus and regulates gene expression. The receptor consists of three primary functional domains: an N-terminal transactivation domain (NTD), a DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD).

Classical androgens — testosterone and dihydrotestosterone (DHT) — bind the LBD indiscriminately across tissues expressing the AR, producing anabolic effects in skeletal muscle and bone alongside androgenic effects in the prostate, skin, and reproductive organs. This lack of tissue selectivity is the central clinical limitation of testosterone as a therapeutic agent.

SARMs like MK-2866 exploit the structural plasticity of the AR’s ligand-binding pocket. Distinct ligand-induced conformational changes in helix 12 (H12) of the LBD alter surface topology, selectively recruiting co-activator or co-repressor proteins depending on cellular context. In anabolic tissue (skeletal muscle, bone), the MK-2866-bound AR conformation preferentially recruits co-activators, driving transcription of anabolic target genes. In androgenic tissue (prostate, seminal vesicles), the same conformation has reduced co-activator recruitment efficiency — producing weaker activation relative to testosterone.

Binding Affinity and Receptor Kinetics

MK-2866 binds the AR with high affinity. Published binding data report a Ki value of approximately 3.8 nM, placing it among the highest-affinity non-steroidal AR ligands characterised to date. The binding interaction is non-covalent and reversible. Molecular docking studies indicate that the cyano group at the para position of the A-ring phenyl moiety forms a key hydrogen bond with Arg752 in the AR LBD, while the trifluoromethyl group on the B-ring contributes hydrophobic packing interactions within a sub-pocket of the binding site.

The hydroxyl group at the chiral centre forms an additional hydrogen bond with Thr877, contributing to the compound’s stereoselectivity — the (S)-enantiomer (active form) binds with substantially higher affinity than the (R)-enantiomer.

Downstream Signalling and Transcriptional Effects

Upon MK-2866 binding, the AR undergoes a conformational change that facilitates: dissociation from heat shock proteins (HSP90, HSP70); homodimerisation; nuclear translocation via importin-mediated transport; androgen response element (ARE) binding at specific DNA sequences (5′-GGTACAnnnTGTTCT-3′) in target gene promoters; and tissue-specific co-regulator recruitment driving transcriptional output.

Key anabolic target genes regulated by AR in skeletal muscle include IGF-1, follistatin, and components of the PI3K/Akt/mTOR pathway. In bone, AR activation promotes osteoblast differentiation and suppresses osteoclastogenesis via RANKL/OPG axis modulation. In the prostate, AR drives expression of PSA (KLK3) and genes promoting cell proliferation — activity that MK-2866 activates at substantially lower efficacy than testosterone in pre-clinical models.

Tissue Selectivity: Pre-Clinical Data

In orchidectomised rat models — the standard pre-clinical model for AR agonist selectivity — key published findings for MK-2866 include:

• Levator ani muscle (anabolic marker): ED50 of 0.03 mg/day; tissue weight restored to 141.9% of intact controls at efficacious doses
• Prostate weight (androgenic marker): ED50 of 0.12 mg/day; 39.2% recovery relative to testosterone propionate
• Seminal vesicle weight: 78.8% recovery — intermediate between prostate and levator ani

The anabolic-to-androgenic ratio of approximately 4:1 is the quantitative expression of MK-2866’s tissue selectivity and the primary metric used to compare SARM candidates in pre-clinical drug development.

Pharmacokinetics

Following intravenous administration in rats (10 mg/kg), MK-2866 exhibits a terminal half-life of approximately 6 hours — significantly longer than structurally related SARMs in the same compound series (2.6–4.0 hours). In human Phase I clinical studies, the terminal elimination half-life extended to 24–36 hours, attributable to species differences in cytochrome P450-mediated metabolism and plasma protein binding.

Oral bioavailability exceeds 80% in pre-clinical models. Primary hepatic metabolism proceeds via CYP3A4-mediated hydroxylation followed by glucuronide conjugation. MK-2866 does not undergo aromatisation to oestradiol (unlike testosterone) and is not a substrate for 5α-reductase — both properties that simplify experimental interpretation in AR-focused research designs.

Receptor Selectivity Counter-Screening

At concentrations used in standard AR research assays (up to 10 µM), MK-2866 does not significantly bind progesterone, oestrogen, glucocorticoid, or mineralocorticoid receptors. This receptor selectivity profile makes it a useful tool for experiments designed to isolate AR-specific effects from the broader nuclear receptor signalling network.

In-Vitro Research Considerations

Researchers using reference-grade MK-2866 in cell culture should note: DMSO vehicle concentrations should be maintained at ≤0.1% v/v; effective free concentrations in serum-containing media are reduced by protein binding (albumin and SHBG in FBS); and AR expression levels vary considerably across cell lines (LNCaP: high endogenous AR; C2C12: low endogenous AR, muscle lineage; MC3T3-E1: osteoblast lineage).

Summary

MK-2866 exerts its biological effects through selective, high-affinity binding to the androgen receptor LBD, inducing tissue-specific conformational changes that preferentially activate anabolic gene programmes while producing attenuated androgenic signalling. Its extended half-life, non-aromatisable structure, and high receptor selectivity make it the best-characterised SARM available for AR research.

All products supplied by Ostarine Australia are pharmaceutical-grade reference compounds for in-vitro laboratory and research use only. Not approved for human or animal consumption. View available MK-2866 research forms →